Cellectar Biosciences, a Madison, WI-based company that is developing drugs with the potential to treat malignant tumors and certain forms of blood cancer, said on Wednesday that it has named John Friend as its chief medical officer, effective April 17. Friend, a physician, previously worked at the Swiss pharmaceutical group Helsinn Therapeutics for more than seven years, Cellectar (NASDAQ: [[ticker:CLRB]]) said in a news release. Most recently, he served as senior vice president of medical and scientific affairs at Helsinn, according to the release.
